Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

6.420 +1.920 (+42.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts
 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
The market is filled with gapping stocks in Friday's session.
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment. 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics
 
Via Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
 
Via Benzinga
These stocks that are showing activity before the opening bell on Friday.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts
 
Via Benzinga
What 5 Analyst Ratings Have To Say About 4D Molecular Therapeutics
 
Via Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
These stocks are moving in today's after hours session
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics
 
Via Benzinga
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study
4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements. 
Via Benzinga
The Latest Analyst Ratings For 4D Molecular Therapeutics
 
Via Benzinga
Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
 
Via Benzinga
Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
 
Via Benzinga
Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to... 
Via Benzinga
FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS for Q2 2024
FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Analyst Expectations For 4D Molecular Therapeutics's Future
 
Via Benzinga
4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate
4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing... 
Via Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
 
Via Benzinga
Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released
4D Molecular Therapeutics shares interim data from the 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.